CapsoVision (CV) Current Deferred Revenue (2024 - 2026)
CapsoVision (CV) posted Current Deferred Revenue of $177000.0 for Q4 2025, up 66.98% sequentially from $106000.0 in Q3 2025, and up 34.09% YoY from $132000.0 in Q4 2024.
CapsoVision (CV) Current Deferred Revenue (2024 - 2026) Analysis & Trends
CapsoVision has reported Current Deferred Revenue for 2 years, with the latest figure at $177000.0 in Q4 2025.
- Quarterly Current Deferred Revenue rose 34.09% year-over-year to $177000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $177000.0 (up 34.09% YoY) and the FY2025 annual result came in at $177000.0, up 34.09% from the prior year.
- Current Deferred Revenue advanced to $177000.0 in Q4 2025 per CV's latest filing, from $106000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $177000.0 in Q4 2025 and troughed at $97000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | CapsoVision | 295.13 Mn | 286.05 Mn | 1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140,000.00 |
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Dec 31, 2024 | 132,000.00 |